PremiumRatingsAscendis Pharma’s Strong Yorvipath Launch and Promising Pipeline Boost Buy Rating and Price Target Promising Outlook for Ascendis Pharma: Strong Yorvipath Sales and Positive Market Feedback Justify Buy Rating Ascendis Pharma upgraded to Overweight from Equal Weight at Morgan Stanley PremiumThe FlyAscendis Pharma price target raised to $245 from $200 at JPMorgan Ascendis Pharma’s Yorvipath Drives Strong US Market Performance and Promising Long-term Outlook, Justifying Buy Rating Ascendis Pharma Reports Strong Q1 2025 Performance PremiumThe FlyAscendis Pharma reports Q1 EPS (EUR 1.58) vs. ( EUR 2.30) last year Ascendis Pharma Schedules 2025 Annual General Meeting Ascendis Pharma A/S (ASND) Q1 Earnings Cheat Sheet 
